GHLV issued 533,333 units of the completed phase 2 of its previously announced US$2,000,000 private placement to one investor at a price of US$0.75 per unit for gross proceeds of US$400,000.
"As a result of the closing of the second tranche of the private placement, we have now raised $1,000,000 of the contemplated total $2,000,000 private placement as announced previously. We expect that the Company will complete the entire financing of $2,000,000 and we aim to use the proceeds of the financing to carry out the clinical trials of our male sexual enhancement drug, X-Excite" stated Dr. Hassan Salari, Global Health President and CEO.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock NewsletterAbout Global Health Ventures, Inc.
The Company is a specialty pharma focused on the over-the-counter drug market. The Company is developing a new proprietary platform technology that delivers many approved drugs via the sublingual (under the tongue) route. This unique method delivers low dose drugs directly to the blood stream, bypassing all the side effects of digestive and liver system breakdowns, while maintaining product efficacy. The Company currently has five products in various stage of development.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our websiteAbout Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
